Clinical trial
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid…
NCT00463346 · Yale University, Other · Completed
Key facts
| NCT number | NCT00463346 |
|---|---|
| Title | Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism |
| Official title | Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism |
| Lead sponsor | Yale University, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alcohol Dependence, Schizophrenia |
| Intervention type | Drug |
| Interventions | Acamprosate, Placebo |
| Enrollment | 23 |
| Start date | Sep 1, 2006 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Apr 20, 2007 |
| Last update posted | Mar 31, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: